Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis

• Status: Terminated
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The adequate treatment of the American tegumentary leishmaniasis is crucial since the disease, differently from the caused by the Old World species, is painful and not self-healing and may lead to the disfiguring mucosal involvement. So far, pentavalent antimony compounds have been considered the treatment of choice for cutaneous leishmaniasis (CL), however, these drugs present high frequency of side effects and important disadvantages as parenteral administration and need for careful renal and cardiac monitoring. Azithromycin is a macrolide antibiotic, non-expensive, largely commercially available that has shown in-vitro and in vivo activity against different species of Leishmania.

The main objective of this study is to evaluate the efficacy and safety of oral azithromycin for the treatment of CL. The efficacy of oral treatment of azithromycin 500 mg/day for 20 days is going to be compared with the standard treatment of intramuscular injections of 20 mg/Kg/day of pentavalent antimonials (Glucantime®) for 20 days in patients with CL from two endemic regions of Brazil: the metropolitan region of Belo Horizonte and Montes Claros (MG)in the southeast Brazil and in Corte de Pedras (Bahia), Northeastern Brazil. The patients follow up lasts for 12 months.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ana Rabello
• Collaborator: Conselho Nacional de Desenvolvimento Científico e Tecnológico
• Treatments: Azithromycin; Meglumine Antimoniate

Criteria

Inclusion Criteria:

• Patients older than 14 and younger than 65 years old

• Skin lesions with clinical suggestion of cutaneous leishmaniasis and positive leishmanin skin test(Montenegro test)or parasitological (direct observation of leishmania amastigotes, leishmania in vitro culture from aspirates, histopathological) and molecular(Polymerase Chain Reaction - PCR)samples.

• No use of oral potentially antileishmanial drugs, or topics throughout the term of the current injury.

• Absence of disseminated leishmaniasis.

• Absence of mucosal involvement.

• Agreement to participate in the study and signed the informed consent.

Exclusion Criteria:

• Diabetes mellitus, kidney diseases, liver or cardiac diseases, tuberculosis, malaria.

• Pregnancy

• lactating mothers

• Breast feeding

• Cutaneous lesion with bacterial infection for which antibiotics need to be prescribed

• More than six cutaneous lesions

• Previous history of cutaneous or mucosal leishmaniasis

• Use of drugs with potential pharmacological interactions with antimonials as anti-arrhythmic or tricycle anti-depressives

• Previous intolerance to azithromycin or other macrolides or N-methylglucamine

• Abusive alcohol ingestion according to the CAGE questionnaire